M Bassetti

Summary

Affiliation: San Martino University Hospital
Country: Italy

Publications

  1. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis. 2010;10:287 pubmed publisher
    ..7%): Considering the lack of data on tigecycline for critically ill patients, we think that the reported data of our clinical experience despite some limitations can be useful for clinicians. ..
  2. Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 2008;3:649-60 pubmed publisher
    ....
  3. request reprint
    Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. Current status of newer carbapenems. Curr Med Chem. 2009;16:564-75 pubmed
    ..We reviewed the principal characteristics of the novel carbapenems and their clinical implications. We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem. ..
  4. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, De Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36:459-61 pubmed publisher
    ..We recommend further randomised controlled prospective studies with higher doses of daptomycin. ..
  5. request reprint
    Bassetti M, Repetto E, Mikulska M, Miglino M, Clavio M, Gobbi M, et al. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother. 2009;21:211-4 pubmed
    ..The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed...
  6. Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice?. Int J Antimicrob Agents. 2009;34 Suppl 1:S15-9 pubmed publisher
    ..Prompt, appropriate treatment, guided by the site and type of infection and risk factors for HA-MRSA or CA-MRSA, increases the chances of a successful outcome and is urgently needed. ..

Locale

Detail Information

Publications6

  1. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis. 2010;10:287 pubmed publisher
    ..7%): Considering the lack of data on tigecycline for critically ill patients, we think that the reported data of our clinical experience despite some limitations can be useful for clinicians. ..
  2. Bassetti M, Righi E, Esposito S, Petrosillo N, Nicolini L. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 2008;3:649-60 pubmed publisher
    ....
  3. request reprint
    Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. Current status of newer carbapenems. Curr Med Chem. 2009;16:564-75 pubmed
    ..We reviewed the principal characteristics of the novel carbapenems and their clinical implications. We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem. ..
  4. Bassetti M, Nicco E, Ginocchio F, Ansaldi F, De Florentiis D, Viscoli C. High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents. 2010;36:459-61 pubmed publisher
    ..We recommend further randomised controlled prospective studies with higher doses of daptomycin. ..
  5. request reprint
    Bassetti M, Repetto E, Mikulska M, Miglino M, Clavio M, Gobbi M, et al. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother. 2009;21:211-4 pubmed
    ..The international literature regarding opportunistic infections after immunosuppressive therapy with alemtuzumab with particular attention on fungal infections has also been reviewed...
  6. Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice?. Int J Antimicrob Agents. 2009;34 Suppl 1:S15-9 pubmed publisher
    ..Prompt, appropriate treatment, guided by the site and type of infection and risk factors for HA-MRSA or CA-MRSA, increases the chances of a successful outcome and is urgently needed. ..